The convergence of ion channel function and enzymatic activity in a single protein represents an untapped frontier for treating complex neurological conditions. TRPM7 kinase offers precisely this dual therapeutic opportunity, potentially addressing multiple pathological mechanisms simultaneously rather than targeting isolated symptoms. This bifunctional protein operates as both a magnesium-permeable ion channel and a serine-threonine kinase, positioning it uniquely in cellular signaling networks critical to neuronal health and survival. The kinase domain regulates diverse cellular processes including proliferation, migration, and apoptosis, while its channel function controls magnesium homeostasis essential for neuronal excitability and synaptic transmission. Pharmaceutical researchers have identified specific modulators that can selectively target either the kinase activity or channel function, enabling precision approaches to different aspects of neurological pathology. Current drug development programs focus on conditions where TRPM7 dysregulation contributes to disease progression, including stroke, neurodegenerative disorders, and epilepsy. The multimodal targeting approach represents a significant departure from conventional single-mechanism therapeutics that often fall short in complex neurological diseases. However, the dual functionality that makes TRPM7 attractive also complicates drug design, as compounds must navigate the delicate balance between beneficial modulation and disruption of normal cellular processes. Early preclinical data suggest that selective TRPM7 inhibition can provide neuroprotection without compromising essential magnesium signaling, though translating these findings to human therapeutics remains challenging given the protein's fundamental role in cellular physiology.